Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit
Abstract We aimed to construct a novel population pharmacokinetics (PPK) model of doripenem (DRPM) for Japanese patients in intensive care unit, incorporating the clearance of DRPM by continuous renal replacement therapy (CRRT). Twenty-one patients treated with DRPM (0.25 or 0.5 g) by intravenous in...
Guardado en:
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/27a65936ad8a48dda497e5e8845681d8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:27a65936ad8a48dda497e5e8845681d8 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:27a65936ad8a48dda497e5e8845681d82021-12-02T11:57:57ZPopulation pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit10.1038/s41598-020-79076-62045-2322https://doaj.org/article/27a65936ad8a48dda497e5e8845681d82020-12-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-79076-6https://doaj.org/toc/2045-2322Abstract We aimed to construct a novel population pharmacokinetics (PPK) model of doripenem (DRPM) for Japanese patients in intensive care unit, incorporating the clearance of DRPM by continuous renal replacement therapy (CRRT). Twenty-one patients treated with DRPM (0.25 or 0.5 g) by intravenous infusion over 1 h were included in the study. Nine of the 21 patients were receiving CRRT. Plasma samples were obtained before and 1, 2, 4, 6 and 8 h after the first DRPM administration. PPK analysis was conducted by nonlinear mixed effects modeling using a two-compartment model. Total clearance (CLtotal) in the model was divided into CRRT clearance (CLCRRT) and body clearance (CLbody). The final model was: CLtotal (L h−1) = CLbody(non-CRRT) = 3.65 × (Ccr/62.25)0.64 in the absence of CRRT, or = CLbody(CRRT) + CLCRRT = 2.49 × (Ccr/52.75)0.42 + CLCRRT in the presence of CRRT; CLCRRT = QE × 0.919 (0.919 represents non-protein binding rate of DRPM); V1 (L) = 10.04; V2 (L) = 8.13; and Q (L h−1) = 3.53. Using this model, CLtotal was lower and the distribution volumes (V1 and V2) tended to be higher compared to previous reports. Also, Ccr was selected as a significant covariate for CLbody. Furthermore, the contribution rate of CLCRRT to CLtotal was 30–40%, suggesting the importance of drug removal by CRRT. The population analysis model used in this study is a useful tool for planning DRPM regimen and administration. Our novel model may contribute greatly to proper use of DRPM in patients requiring intensive care.Ko NonoshitaYosuke SuzukiRyota TanakaTetsuya KanekoYoshifumi OhchiYuhki SatoNorihisa YasudaKoji GotoTakaaki KitanoHiroki ItohNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 10, Iss 1, Pp 1-11 (2020) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Ko Nonoshita Yosuke Suzuki Ryota Tanaka Tetsuya Kaneko Yoshifumi Ohchi Yuhki Sato Norihisa Yasuda Koji Goto Takaaki Kitano Hiroki Itoh Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit |
| description |
Abstract We aimed to construct a novel population pharmacokinetics (PPK) model of doripenem (DRPM) for Japanese patients in intensive care unit, incorporating the clearance of DRPM by continuous renal replacement therapy (CRRT). Twenty-one patients treated with DRPM (0.25 or 0.5 g) by intravenous infusion over 1 h were included in the study. Nine of the 21 patients were receiving CRRT. Plasma samples were obtained before and 1, 2, 4, 6 and 8 h after the first DRPM administration. PPK analysis was conducted by nonlinear mixed effects modeling using a two-compartment model. Total clearance (CLtotal) in the model was divided into CRRT clearance (CLCRRT) and body clearance (CLbody). The final model was: CLtotal (L h−1) = CLbody(non-CRRT) = 3.65 × (Ccr/62.25)0.64 in the absence of CRRT, or = CLbody(CRRT) + CLCRRT = 2.49 × (Ccr/52.75)0.42 + CLCRRT in the presence of CRRT; CLCRRT = QE × 0.919 (0.919 represents non-protein binding rate of DRPM); V1 (L) = 10.04; V2 (L) = 8.13; and Q (L h−1) = 3.53. Using this model, CLtotal was lower and the distribution volumes (V1 and V2) tended to be higher compared to previous reports. Also, Ccr was selected as a significant covariate for CLbody. Furthermore, the contribution rate of CLCRRT to CLtotal was 30–40%, suggesting the importance of drug removal by CRRT. The population analysis model used in this study is a useful tool for planning DRPM regimen and administration. Our novel model may contribute greatly to proper use of DRPM in patients requiring intensive care. |
| format |
article |
| author |
Ko Nonoshita Yosuke Suzuki Ryota Tanaka Tetsuya Kaneko Yoshifumi Ohchi Yuhki Sato Norihisa Yasuda Koji Goto Takaaki Kitano Hiroki Itoh |
| author_facet |
Ko Nonoshita Yosuke Suzuki Ryota Tanaka Tetsuya Kaneko Yoshifumi Ohchi Yuhki Sato Norihisa Yasuda Koji Goto Takaaki Kitano Hiroki Itoh |
| author_sort |
Ko Nonoshita |
| title |
Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit |
| title_short |
Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit |
| title_full |
Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit |
| title_fullStr |
Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit |
| title_full_unstemmed |
Population pharmacokinetic analysis of doripenem for Japanese patients in intensive care unit |
| title_sort |
population pharmacokinetic analysis of doripenem for japanese patients in intensive care unit |
| publisher |
Nature Portfolio |
| publishDate |
2020 |
| url |
https://doaj.org/article/27a65936ad8a48dda497e5e8845681d8 |
| work_keys_str_mv |
AT kononoshita populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit AT yosukesuzuki populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit AT ryotatanaka populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit AT tetsuyakaneko populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit AT yoshifumiohchi populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit AT yuhkisato populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit AT norihisayasuda populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit AT kojigoto populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit AT takaakikitano populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit AT hirokiitoh populationpharmacokineticanalysisofdoripenemforjapanesepatientsinintensivecareunit |
| _version_ |
1718394737424072704 |